Premium
Association of Coloproctology of Great Britain & Ireland ( ACPGBI ): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) ‐ Introduction
Author(s) -
Moran Brendan,
Karandikar Sharad,
Geh Ian
Publication year - 2017
Publication title -
colorectal disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.029
H-Index - 89
eISSN - 1463-1318
pISSN - 1462-8910
DOI - 10.1111/codi.13702
Subject(s) - medicine , colorectal cancer , family medicine , cancer
The ACPGBI has been at the forefront in developing guidelines, position statements and national training programs related to both common, and complex, colorectal pathology. These initiatives often serve as a global reference in this challenging field. The Association of Coloproctology of Great Britain and Ireland (ACPGBI) 2007 Colorectal Cancer Management Guidelines have been the basis for continuous evolution in the way these cancers are managed. The current update aims to clarify many recent developments on the multidisciplinary management of colorectal cancer and to provide links to relevant publications. The recommendations made within these guidelines have been graded according to the Oxford Centre for Evidencebased Medicine – levels of evidence (www.cebm.net/ oxford-centre-evidence-based-medicine-levels-evidencemarch-2009/). We hope that these guidelines will offer a framework for clinicians and MDT’s to tailor treatments to suit individual patients. We also hope to direct future research and debate in a rapidly evolving field. A substantial part of the workload of colorectal units is to not only exclude diagnosis of cancer but to manage cancer of the colon, rectum and anal canal. Access to information through technology, and particularly the internet, has changed perceptions and expectations of cancer patients, their carers and clinicians. The general public and healthcare providers continue to shift focus towards cancer prevention and early diagnosis. At the other end of the spectrum, patients with locally advanced, recurrent or metastatic cancer are increasingly being considered for tailored multimodal therapy, based on molecular biology and pharmaceutical advances. In the UK, through the NCRI Colorectal Cancer Clinical Trials Group and numerous other research organizations, we are proud of our record of being at the forefront of designing and completing many internationally acclaimed oncological and surgical trials. These have been instrumental in shaping our current clinical practice. We must continue to build on this foundation by developing and recruiting into new trials to further improve treatment.